Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255565 · ClinicalTrials.gov registry record · Phase 4
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
A Phase 4 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT02255565 is a Phase 4 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 36 participants.
The verdict
NCT02255565, a Phase 4 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
Interventions
- DRUG Very Low Dose Quillivant XR
- DRUG Low Dose Quillivant XR
- DRUG Moderate Dose Quillivant XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255565
The ClinicalTrials.gov registry entry for NCT02255565 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Very Low Dose Quillivant XR is the first listed.
NCT02255565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255565 about?
NCT02255565 is a clinical study titled "Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study". The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
What is the current status of trial NCT02255565?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2014-09. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02255565?
The interventions under investigation include: Very Low Dose Quillivant XR (DRUG), Low Dose Quillivant XR (DRUG), Moderate Dose Quillivant XR (DRUG).
Who is sponsoring clinical trial NCT02255565?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.